Search Results for 'gemcitabine cisplatin'
-
Search Results
-
Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in patients (pts) with resected lymph node (LN)-positive extrahepatic cholangiocarcinoma (CCA): A multicenter, open-label, randomized, phase 2 study (STAMP).
PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement.
Gemcitabine plus cisplatin versus non-gemcitabine and cisplatin regimens as neoadjuvant treatment for cholangiocarcinoma patients prior to liver transplantation.
NEO-GAP: A phase II single-arm prospective feasibility study of neoadjuvant gemcitabine/cisplatin/nab-paclitaxel for resectable high-risk intrahepatic cholangiocarcinoma.
A prospective, multicenter, phase II trial of albumin-paclitaxel plus cisplatin versus gemcitabine plus cisplatin in first-line treatment of advanced biliary tract tumors.
Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma
Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma
[Successful R0 Resection of Hilar Cholangiocarcinoma Invading the Inferior Vena Cava through Left Trisegmentectomy with Combined Resection of the Portal Vein and Inferior Vena Cava after Gemcitabine/Cisplatin Combination Chemotherapy-A Case Report]
Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma.
TOPAZ-1: Durvalumab Plus Gemcitabine and Cisplatin Could Become New First-Line Standard of Care for Advanced Biliary Tract Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.22.200807/full/
Thanks to American Society of Clinical Oncology for this piece.
Gavin
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study
Selective internal radiation therapy (SIRT) with Y90 resin microspheres to gemcitabine/cisplatin
” The addition of selective internal radiation therapy with Y90 resin microspheres to gemcitabine/cisplatin resulted in a median overall survival of 21.6 months for patients with inoperable intrahepatic cholangiocarcinoma, according to prospective phase 2 data.”
Thanks to OncLive for this piece.
Gavin
Efficacy and Safety of Gemcitabine Plus Cisplatin as Potential Preoperative Chemotherapy in Locally Advanced Intrahepatic, Perihilar, and Mid-Cholangiocarcinoma: A Retrospective Cohort Study
Hi Frances,
Thank you for posting your latest blog chapter. Such a beautiful tribute to your mom, and to the bond you shared.
I wanted to provide a little information as to whether your mom should have been treated with Gem-Cis and not with Gemcitabine alone. I looked back at the medical literature and guidelines from that time. Gem-Cis became the standard of care first-line treatment for unresectable cholangiocarcinoma due to the positive results of a trial in Great Britain titled ABC-02. This trial demonstrated that the Gem-Cis combination therapy was more effective than Gemcitabine alone.
There was one group, however, within the population of patients participating in ABC-02 who saw little benefit from adding Cisplatin. This group was patients who were in poorer health, defined as having ECOG performance status 2 (PS2). ECOG scores run from zero to five. Patients who are extremely sick or weak are not good candidates for clinical trials, so the ABC-02 ECOG PS2 participants weren’t in dire poor health. Within the group of patients participating in the trial, however, the ECOG PS2 subgroup had the most impaired health status. The trial results indicated that the ECOG PS2 patients who were treated with Gem-Cis had similar (not better) outcomes to those treated just with Gemcitabine. Reporting on ABC-02 results often notes the ECOG PS2 group saw little benefit from adding Cisplatin. I put a link below to an article from early 2014 that states this finding.
With this finding a recommendation to treat patients in a poor health status with Gemcitabine alone made its way into various guideline documents around that time. Judging from some of the stories we have seen from caretakers, a related consideration has been the question of whether Cisplatin’s side effects could be well tolerated by patients whose health status was not robust. Not being a doctor, I am not in a position to assess whether this consideration would have been relevant for your mother, but wanted to pass this along as a possible explanation for the care offered to your mother.
The medical science for our rare cancer has evolved rapidly, and patients diagnosed in 2021 may have more treatment options than was the case seven years ago. Still, cholangiocarcinoma can be symptomless in its early stages, and is often not diagnosed until it is very advanced, blindsiding patients and their families. Your blog describes so well how a family coped with a devastating late-stage diagnosis. Thank you again for sharing your story.
Here is the link: https://pubmed.ncbi.nlm.nih.gov/24351397/
Regards, Mary
Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis
